DUBLIN--(BUSINESS WIRE)--The "GCC Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022" report has been added to Research and Markets' offering.
The generic drugs market in the GCC reached a value of nearly US$ 1,550 Million in 2016, exhibiting a CAGR of 15% during 2009-2016.
One of the major factors that is expected to boost the market is the mounting pharmaceutical manufacturing capacity in the region boosted by the plans for regional integration and a greater emphasis on drugs produced within the GCC. The efforts to reduce dependence on imported drugs will further stimulate domestic manufacturing of drugs, particularly generics. Moreover, the government of Saudi Arabia, Oman and UAE have started campaigns aimed at boosting awareness towards the substitution of branded drugs by generics. However, the preference for branded drugs supported by a significant affluent population and the demand for sophisticated pharmaceuticals can hamper the market growth. Overall, the market is expected to continue its growth, reaching a value of more than US$ 1500 Million by 2022.
The report has segmented the GCC generic drugs market on the basis of countries. Currently, Saudi Arabia represents the largest market in the region, accounting for more than a half of the total market share. This can be attributed to the rapid economic development and the subsequent rise in the cases of lifestyles diseases in the country. The lenient data exclusivity laws in the country have also boosted the market. The report has further analyzed the competitive landscape of the market and provides the profiles of the key players operating in it.
Some of the key players include SPIMACO, Pfizer, Novartis, TPMC and Hikma.
Key Topics Covered:
1 Preface
2 Scope and Methodology
3 Executive Summary
4 Introduction
5 Global Generic Drug Industry
6 GCC Generic Drug Industry
7 Performance of Key Regions
8 Competitive Landscape
9 Generic Drug Manufacturing Process
10 Project Details, Requirements and Costs Involved
11 Loans and Financial Assistance
12 Project Economics
13 Key Player Profiles
- SPIMACO
- Pfizer
- Novartis
- TPMC
- Hikma
For more information about this report visit https://www.researchandmarkets.com/research/g884cc/gcc_generic_drug
